Poly Medicure Limited has appointed Mr. Indranil Mukherjee as Chief Executive Officer - Asia Pacific and India Business effective June 1, 2026. The appointment, approved by the Board of Directors via circular resolutions based on the recommendation of the Nomination and Remuneration Committee, strengthens the company's leadership team. Mr. Mukherjee will report directly to the Managing Director and has been categorized as Senior Management Personnel (SMP) under the SEBI Listing Regulations.

Mr. Indranil Mukherjee is a seasoned medical technology executive with over 30 years of broad-based leadership experience. His expertise spans critical care, infusion therapy, renal care, surgical instruments, vascular systems, wound care, and implantable devices. He has a demonstrated track record of acting as a change agent, scaling up business, leading market expansion, managing M&A and integration, and executing strategy.

He built the foundational years of his career at B. Braun, managing the Hospital Care, Outpatient Market, and Aesculap (Vascular) portfolios across India. He later transferred to B. Braun's headquarters in Germany as Global Sales Manager in 2010 and subsequently served as Regional Head for Hospital Care at the Asia Pacific headquarters in Penang, Malaysia. As Managing Director at B. Braun Group in India, he delivered a turnaround and sustained profitable growth across multiple product lines spanning three manufacturing plants and a team of over 2,000 colleagues.

Most recently, Mr. Mukherjee served as Group Chief Executive Officer of Translumina Therapeutics, a global cardiovascular implants company with operations in India and Germany. His career reflects deep expertise across the full spectrum of medical devices, from consumables to capital equipment and implants, combined with a proven track record of building high-performance commercial organisations and driving P&L responsibilities at country, regional, and global levels. He graduated in Chemistry from St. Xavier's College Ranchi and holds an MBA from Bhopal University, followed by SMP from IIM Calcutta and LBTA from INSEAD Singapore.

Key Appointment Details

Poly Medicure has released the transcript of its earnings conference call held on May 25, 2026, discussing the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported a consolidated revenue of INR1,875 crores for FY26, a growth of 12.3% year-on-year, and provided a revenue guidance of INR2,300 crores to INR2,400 crores for FY27. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

For the full year FY26, standalone revenue was INR1,662 crores, up 4% compared to the previous year. Standalone EBITDA was INR446 crores with a margin of 26.8%, meeting the higher end of the guided range of 25% to 27%. Q4 standalone revenue reached INR443 crores, a 5.2% year-on-year increase, marking the highest ever standalone quarter with an EBITDA margin of 27.3%.

Consolidated revenue for Q4 was INR534 crores, up 21% year-on-year, driven by domestic growth of 25% and international business growth of 19%. The consolidated EBITDA for Q4 was INR112 crores, impacted by the consolidation of low-margin acquisitions and one-time regulatory and cost provisions of INR9 crores in an international subsidiary.

Strategic Guidance

Management provided a revenue guidance of INR2,300 crores to INR2,400 crores for FY27 on a consolidated basis, which includes the full-year consolidation of acquisitions PendraCare and Citieffe. On a standalone basis, revenue is guided between INR1,900 crores and INR1,950 crores. The company expects standalone EBITDA margins to remain in the 25% to 27% range, while consolidated EBITDA margins are projected between 23% and 25%.

Operational Highlights

The company launched approximately 35 new products across the group in FY26. On the Renal platform, around 450 dialysis machines were placed, taking the installed capacity to approximately 1,000 machines. The company also announced the acquisition of Medyneo in Brazil to fast-track entry into the South American market. Capex for FY26 was INR296 crores, with an expected spend of INR200 crores to INR225 crores in FY27.

Segment Performance

Infusion Therapy accounted for 50% of the revenue in Q4 FY26, down from 57% in Q4 FY25, while the Renal segment contributed 11%. The shift in revenue mix towards higher technology segments is expected to improve gross margins over time. The company holds a strong cash reserve of INR842 crores to fund strategic initiatives.